Andere Sprachen CSPC Pharmaceutical Group Ltd.

Aktien

548183

HK1093012172

1093

Verzögert Hong Kong S.E. Andere Börsenplätze 07:07:24 02.05.2024			% 5 Tage	% 1. Jan.
6,7 ^HKD	+3,40 %		+10,74 %	-7,71 %

26.04.	CSPC Pharmaceutical Group Limited gibt bekannt, dass ein hochselektiver Mat2A-Inhibitor (SYH2039) die Zulassung für klinische Studien in den USA erhalten hat	CI
24.04.	EBT von CSPC Pharmaceutical kauft 8,5 Millionen Aktien	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

CSPC Pharmaceutical Group Limited Proposes Final Dividend for the Year Ended 31 December 2023	26.04.
CSPC Pharmaceutical Group Limited Announces Highly Selective Mat2A Inhibitor Obtains Clinical Trial Approval in the U.S	26.04.
CSPC Pharmaceutical's EBT Buys 8.5 Million Shares	24.04.
CSPC Pharmaceutical Group Limited and CSPC Holdings Company Limited Enter into Master Sales Agreement	19.04.
China's drugmakers can't sell mRNA shots but haven't quit yet	19.04.
CSPC Pharmaceutical Group Limited commences an Equity Buyback Plan for 1,190,321,973 shares, representing 10% of its issued share capital, under the authorization approved on May 31, 2023.	16.04.
CSPC Pharma Secures Chinese Nod for Weight Managment Drug Trials	26.03.
CSPC Pharmaceutical Group Limited Obtains Clinical Trial Approval Granted by the National Medical Products Administration	25.03.
CSPC Pharmaceutical’ Blood Sugar Drug Gets Registration Approval from Chinese Regulator	22.03.
CSPC Pharmaceutical Group Limited Announces Dapagliflozin Tablets Obtains Drug Registration Approval	22.03.
CSPC Pharmaceutical's Cancer Drug Gets China Nod for Clinical Trials	21.03.
CSPC Pharmaceutical Group Limited Announces Antibody-Drug Conjugate SYS6023 Obtains Clinical Trial Approval by the National Medical Products Administration of the People's Republic of China to Conduct Clinical Trials in China	20.03.
CSPC Pharmaceutical Group Limited Proposes Ordinary Final Cash Dividend for the Year Ended 31 December 2023, Payable on 26 June 2024	20.03.
CSPC Pharmaceutical's Profit Falls 4% on Lower Revenue, Misses Estimates	20.03.
CSPC Pharmaceutical Group Limited Reports Earnings Results for the Full Year Ended December 31, 2023	20.03.
CSPC Pharma Obtains Clinical Trial Approval in China for Anti-Tumor Drug	19.03.
CSPC Pharmaceutical Group Limited Announces Highly Selective MAT2A Inhibitor Obtains Clinical Trial Approval from the National Medical Products Administration of the People's Republic of China to Conduct Clinical Trials in China	18.03.
CSPC Pharmaceutical Obtains New Indication Nod for Mingfule Injection	05.02.
CSPC Baike's 2023 Profit Reaches 859 Million Yuan	25.01.
U.S. Regulator Allows CSPC Pharmaceutical to Conduct Clinical Trials for Anti-Tumor Drug	15.01.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen CSPC Pharmaceutical Group Ltd.

Aktien

548183

HK1093012172

1093

Andere Sprachen

Filter